Evaluation of the efficacy and safety of ramucirumab combined with nab-paclitaxel, lobaplatin, and S-1 in neoadjuvant and conversion therapy for advanced gastric cancer: A study protocol of prospective single-center, randomized controlled and open label clinical trial (RNPLS-01)

MLA

Juan Wang, et al. “Evaluation of the Efficacy and Safety of Ramucirumab Combined with Nab-Paclitaxel, Lobaplatin, and S-1 in Neoadjuvant and Conversion Therapy for Advanced Gastric Cancer: A Study Protocol of Prospective Single-Center, Randomized Controlled and Open Label Clinical Trial (RNPLS-01).” Heliyon, vol. 10, no. 8, Apr. 2024. EBSCOhost, https://doi.org/10.1016/j.heliyon.2024.e29485.

APA

Juan Wang, Guanghui Xu, Shushang Liu, Yuxuan Ma, Shu Wang, Mengbin Li, Yan Zhao, Haoyuan Wang, Yuhao Wang, Chaosheng Peng, Huade Huo, Haolin Li, Gang Ji, & Jianjun Yang. (2024). Evaluation of the efficacy and safety of ramucirumab combined with nab-paclitaxel, lobaplatin, and S-1 in neoadjuvant and conversion therapy for advanced gastric cancer: A study protocol of prospective single-center, randomized controlled and open label clinical trial (RNPLS-01). Heliyon, 10(8). https://doi.org/10.1016/j.heliyon.2024.e29485

Chicago

Juan Wang, Guanghui Xu, Shushang Liu, Yuxuan Ma, Shu Wang, Mengbin Li, Yan Zhao, et al. 2024. “Evaluation of the Efficacy and Safety of Ramucirumab Combined with Nab-Paclitaxel, Lobaplatin, and S-1 in Neoadjuvant and Conversion Therapy for Advanced Gastric Cancer: A Study Protocol of Prospective Single-Center, Randomized Controlled and Open Label Clinical Trial (RNPLS-01).” Heliyon 10 (8). doi:10.1016/j.heliyon.2024.e29485.